Top Stories
The French company's eyonis LCS tool was cleared by the FDA earlier this year to flag lung nodules on low-dose CT scans.
Researchers have developed machine learning algorithms that can detect exacerbations from voice changes up to three days before symptoms appear.
The National Institutes of Health-funded study lays the groundwork for a new kind of blood-based test that could potentially predict symptom onset.
While Insilico will lead initial discovery and design efforts, Takeda will assume further development responsibilities for selected candidates.
The company's lead candidate is designed to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Conference News
Could more complex molecular analysis aid biomarker-driven clinical management of poor-prognosis colorectal cancer?4 Jul 2026New study findings provide support for the use of ctDNA to predict survival...
Munich, Germany – A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research pr...
Wed, Jul 01, 2026 11:52 CETSpermosens AB (publ) (“Spermosens” or the “Company”) provides an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) ...
Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer1 Jul 2026Colon and Rectal Cancer ESMO Gastrointestinal Cancers Congress 2026Tumours with no c...
Submission builds on the X2 platform’s 20X increase in PET sensitivity to further enhance biologic guidance and expand versatility of SCINTIX therapyHAYWARD, Calif.--(BUSINESS WIRE)-- RefleXion Medica...
